The trial successfully met it's endpoints with the

The trial successfully met it's endpoints with the bonus of establishing that P works better than expected in the moderate cases, which are the cases where the disease is harder to treat. That is efficacy right there folks. So if P performs better in the harder to treat cases why wouldn't CTIX challenge head on the existing drugs in that market and perform the next trial on the moderate/sever cases? It will demonstrate the drugs superior efficacy over the existing therapies on the market and superior delivery method over all the injectables and topicals with the exception of the only other oral drug, Otezla. Just like with Brilacidin; CTIX pitted it against one of the most efficacious market approved drugs (Daptomycin) in the ABSSSI trial to prove it's superiority, CTIX will show P is a better drug.

To say that they didn't get the expected outcome in the mild cases and that is why they are shifting focus to the more sever is an outright lie.
[Stated again: "patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm." ]

When CTIX proves P in a late stage trial and gets the drug to market, then it can be used open label for the mild cases as well as the severe. This will likely be the case since it is oral and so far has demonstrated little to no side effects.
IMO if P improves all cases of psoriasis it will become the standard market treatment.